ArticleScientific reports2018
Functionalization of β-lactam antibiotic on lysozyme capped gold nanoclusters retrogress MRSA and its persisters following awakening.
Article in Scientific reports, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 83 citations in OpenAlex.
- Plant Volatile Nanoemulsion Resensitize Pseudomonas aeruginosa to Benzalkonium Chloride.Current microbiology · 2026Article
- Gold Nanoparticle-Based Drug Delivery System for the Diagnosis and Treatment of Bacterial Meningitis.Current drug delivery · 2025Review
- Autologous serum protein stabilized silver quantum clusters as host-specific antibacterial agents.Nanomedicine (London, England) · 2024Article
- Metal nanoparticles as inhibitors of enzymes and toxins of multidrug-resistantInfectious medicine · 2023Review
- Biosynthesis Strategy of Gold Nanoparticles and Biofabrication of a Novel Amoxicillin Gold Nanodrug to Overcome the Resistance of Multidrug-Resistant Bacterial Pathogens MRSA andBiomimetics (Basel, Switzerland) · 2023Article
- nanoGold and µGold inhibit autoimmune inflammation: a review.Histochemistry and cell biology · 2023Review
- Prospect of nanomaterials as antimicrobial and antiviral regimen.AIMS microbiology · 2023Review
- Antibacterial metal nanoclusters.Journal of nanobiotechnology · 2022Review
- Gold Nanoclusters as Nanoantibiotic Auranofin Analogues.Advanced healthcare materials · 2022Article
- Recent advances in nanoparticles as antibacterial agent.ADMET & DMPK · 2022Review
- Applications of Lysozyme, an Innate Immune Defense Factor, as an Alternative Antibiotic.Antibiotics (Basel, Switzerland) · 2021Review
- Advances in the Application of Nanomaterials as Treatments for Bacterial Infectious Diseases.Pharmaceutics · 2021Review
- Therapy of infected wounds: overcoming clinical challenges by advanced drug delivery systems.Drug delivery and translational research · 2021Review
- Hybrid Nanosystems for Biomedical Applications.ACS nano · 2021Review
- Gold Nanoparticles: Can They Be the Next Magic Bullet for Multidrug-Resistant Bacteria?Nanomaterials (Basel, Switzerland) · 2021Review
- Nanotechnological strategies for systemic microbial infections treatment: A review.International journal of pharmaceutics · 2020Review
- Development of coinage metal nanoclusters as antimicrobials to combat bacterial infections.Journal of materials chemistry. B · 2020Review
- A Quantitative Survey of Bacterial Persistence in the Presence of Antibiotics: Towards Antipersister Antimicrobial Discovery.Antibiotics (Basel, Switzerland) · 2020Article
- Fabrication of antibacterial sponge cleaner using gold nanoclusters.IET nanobiotechnology · 2020Article
- Nanoparticle-Based Therapeutic Approach for Diabetic Wound Healing.Nanomaterials (Basel, Switzerland) · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In this study we have reported an efficient antibacterial hybrid fabricated through surface functionalization of lysozyme capped gold nanoclusters (AUNC-L) with β-lactam antibiotic ampicillin (AUNC-L-Amp). The prepared hybrid not only reverted the MRSA resistance towards ampicillin but also demonstrated enhanced antibacterial activity against non-resistant bacterial strains. Most importantly, upon awakening through cis-2-decenoic acid (cis-DA) exposure, the MRSA persister got inhibited by the AUNC-L-Amp treatment. Intraperitoneal administration of this hybrid eliminates the systemic MRSA infection in a murine animal model. Topical application of this nano conjugate eradicated MRSA infection from difficult to treat diabetic wound of rat and accelerated the healing process. Due to inherent bio-safe nature of gold, AUNC-L alone or in the construct (AUNC-L-Amp) demonstrated excellent biocompatibility and did not indicate any deleterious effects in in vivo settings. We postulate that AUNC-L-Amp overcomes the elevated levels of β-lactamase at the site of MRSA antibiotic interaction with subsequent multivalent binding to the bacterial surface and enhanced permeation. Coordinated action of AUNC-L-Amp components precludes MRSA to attain resistance against the hybrid. We proposed that the inhibitory effect of AUNC-L-Amp against MRSA and its persister form is due to increased Amp concentration at the site of action, multivalent presentation and enhanced permeation of Amp through lysozyme-mediated cell wall lysis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.